Roche says divarasib cut risk of death 44% in lung cancer trial
The investigational drug also cut progression or death risk 42% and showed a manageable safety profile in the global Phase III study.
- On Sunday, Genentech, a member of the Roche Group, announced that its experimental lung cancer drug divarasib reduced the risk of death by 44% in the Phase III Krascendo 1 study compared with existing treatments.
- The KRAS G12C mutation occurs in approximately 25% of newly diagnosed lung cancers and is associated with poorer prognosis for patients despite current first-generation treatments.
- In the Krascendo 1 study of 338 adults, divarasib achieved an objective response rate of 58%, significantly outperforming the 32% rate observed with first-generation inhibitors sotorasib or adagrasib.
- Only 4.8% of divarasib patients discontinued treatment due to adverse events, compared to 11.7% receiving earlier-generation options, demonstrating a favorable safety profile consistent with known class effects.
- Presented at the 2026 ESMO Congress and published in The New England Journal of Medicine, these findings position divarasib as a potential new standard of care while Genentech advances the drug through additional Phase III trials.
28 Articles
28 Articles
Next generation KRAS inhibitor divarasib significantly extends lung cancer survival
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from The University of Texas MD Anderson Cancer Center.
Appalachian News-Express
Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy
Research Conducted at Tennessee Oncology's Greco-Hainsworth Centers for Research Contributes to Study Showing Longer Overall Survival with Next-Generation KRAS G12C Therapy
The Manila Times
stocktitan.netRoche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Krascendo 1 study1,2At the time of primary analysis, divarasib achieved a median overall survival of approximately 18 months, compared to 12 months for sotorasib or adagrasib1,2No new safety signals were observed with divarasib; the most co…
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the Phase III Krascendo 1 study At the time of primary analysis, divarasib achieved a median overall survival of approximately 18 months, compared to 12 months […]
Photo: www.echelon.health According to the Swiss pharmaceutical company Roche, an experimental drug for the treatment of lung cancer, divarasib (divarasib), the risk of death of patients in the third phase of a clinical trial compared to existing treatments is 44% - Reduced by. The study involved patients who had non-small cell lung cancer associated with the KRAS G12C mutation and were previously treated. According to Roche, the overall median …
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
